Suppr超能文献

非小细胞肺癌纵隔淋巴结隐匿性微转移的基因诊断与预后

[Gene diagnosis and prognosis of mediastinal lymph node occult micrometastasis in non-small cell lung carcinoma].

作者信息

Wang Zhou, Yin Hongnian, Zhang Lin, Lan Xingang, Li Houwen

机构信息

Department of Thoracic Surgery, Shandong Provincial Hospital, Jinan 250021, China.

出版信息

Zhonghua Zhong Liu Za Zhi. 2002 May;24(3):247-9.

Abstract

OBJECTIVE

To investigate gene diagnosis of occult micrometastasis in the mediastinal lymph node in patients with non-small cell lung carcinoma (NSCLC) and to evaluate its prognostic significance.

METHODS

With mRNA expression of mucoid1 (MUC1) gene examined by RT-PCR, 168 mediastinal lymph nodes taken from 37 pN(0) (negative lymph nodes) NSCLC patients (stage Ia approximately IIb) made up the experiment group. Thrity negative lymph nodes from 14 benign lesions and 30 positive lymph nodes from 15 NSCLC patients served as control. The survival difference between MUC1 mRNA-negative and MUC1 mRNA-positive groups was compared by the chi(2) test.

RESULTS

UC1 mRNA was not identified in the negative-control group (specificity = 100%), but it was identified in 26 of 30 positive-control samples (sensitivity = 86.7%). MUC1 mRNA was identified in 16 (9.5%) of the experiment group from 12 patients whose TNM stage was up-regulated to stage IIIa. The 3-year survival rate (58.3%) of MUC1 mRNA positive group patients with occult micrometastasis in mediastinal lymph node was lower than the 88.0% of MUC1 mRNA negative group (P < 0.05).

CONCLUSION

Occult micrometastasis in the mediastinal lymph node in NSCLC patients can be diagnosed by MUC1 mRNA expression through RT-PCR. Poor prognosis in some pN(0) NSCLC patients may be associated with nodal occult micrometastasis.

摘要

目的

探讨非小细胞肺癌(NSCLC)患者纵隔淋巴结隐匿性微转移的基因诊断方法,并评估其预后意义。

方法

通过逆转录聚合酶链反应(RT-PCR)检测黏蛋白1(MUC1)基因的mRNA表达,以37例pN(0)(阴性淋巴结)NSCLC患者(Ia期至IIb期)的168个纵隔淋巴结组成实验组。14例良性病变患者的30个阴性淋巴结和15例NSCLC患者的30个阳性淋巴结作为对照。采用卡方检验比较MUC1 mRNA阴性组和阳性组的生存差异。

结果

阴性对照组未检测到MUC1 mRNA(特异性 = 100%),但30个阳性对照样本中有26个检测到(敏感性 = 86.7%)。实验组中有16个(9.5%)检测到MUC1 mRNA,这些样本来自12例TNM分期上调至IIIa期的患者。纵隔淋巴结存在隐匿性微转移的MUC1 mRNA阳性组患者的3年生存率(58.3%)低于MUC1 mRNA阴性组的88.0%(P < 0.05)。

结论

通过RT-PCR检测MUC1 mRNA表达可诊断NSCLC患者纵隔淋巴结隐匿性微转移。部分pN(0) NSCLC患者预后不良可能与淋巴结隐匿性微转移有关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验